Proactive Investors - Run By Investors For Investors

OptiBiotix Health aiming to be big in Japan with latest deal

Following hard on the heels of a commercial deal covering the Baltic area, OptiBiotix Health plc (LON:OPTI) has signed an agreement that will see its breakthrough cholesterol-lowering bacteria strain distributed in Japan. Founder and CEO Stephen O'Hara talks Proactive London through OptiBiotix's last two RNS's and explains how they are inter-related. O'Hara also explains how he has an eye for an emerging trend and how this product, in his view, is one of those key moments.
For the UK group has negotiated an exclusive tie-up with the EIWA Trading Co for its LPLDL product. OptiBiotix will ship an agreed minimum volume of the cholesterol and blood pressure-reducing probiotic, Lactobacillus plantarum, which rises over the term of the three-year contract.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use